New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne

The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on the NHS to treat Duchenne muscular dystrophy.

Vamorolone, also known by the brand name Agamree, will be available to treat people with Duchenne aged 4 and older.

The Duchenne Research Fund has helped nurture the development of vamorolone over the last ten years in a ground-breaking example of venture philanthropy.


An alternative to corticosteroids

Vamorolone, produced by Santhera Pharmaceuticals, was created as an alternative to existing corticosteroids, also called glucocorticoids, which are routinely used in the treatment of Duchenne as they can reduce muscle inflammation and maintain muscle strength. Steroid treatment has several negative side-effects – some Duchenne patients do not tolerate it well or at all, so the approval of vamorolone now gives their neuromuscular consultant a new treatment option for them.


Duchenne Research Fund’s role in developing vamorolone

Fuelled by a desire to provide more treatment options for Duchenne, we invested in and supported vamorolone’s development from the initial laboratory research.

Together with our partner charities, Duchenne UK and Joining Jack, we invested £750,000 towards a Phase 1 clinical trial in boys with Duchenne in 2015, spearheaded by ReveraGen BioPharma. We also helped fund the clinical research site for the vamorolone Phase 2 trial, as well as the post of Professor Michela Guglieri, who was Principal Investigator. This then enabled ReveraGen to win a £6 million grant from Europe’s Horizon 2020 to support the development of vamorolone.

DRF’s medical trustee Dr Sarah Shelley welcomed NICE’s announcement: “We first invested in vamorolone when there were very few Duchenne treatments on the horizon. We are proud that it will now be available on the NHS, offering clinicians an alternative to existing steroids for young people with Duchenne. The return on investment we have made from the vamorolone programme will continue to be invested into Duchenne research.”

Sheli Rodney, Emily Reuben, Prof Katie Bushby, Prof Michela Guglieri, Alex Johnson, Eric Hoffman

Pictured: some of the key people behind the development of vamorolone – Sheli Rodney (Director of Operations, Duchenne Research Fund), Emily Reuben OBE (Co-founder and Chief Executive of Duchenne UK), Professor Katie Bushby (Newcastle University), Professor Michela Guglieri (Newcastle University), Alex Johnson OBE (Co-founder of Duchenne UK and Chief Executive of Joining Jack), Professor Eric Hoffman (Binghamton University)


Vamorolone in the UK

Vamorolone was approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in January this year, but was initially rejected by NICE for use in NHS England in March this year.

NICE’s new decision to approve it will apply within NHS England which must make sure it is as a treatment option available within three months. As NICE guidance is usually adopted in Wales and Northern Ireland, it is expected to be soon available there too. The Scottish Medicines Consortium (SMC) is currently appraising vamorolone for use on the NHS.

Our DMD Care UK programme will be publishing information materials for patients and families about vamorolone and steroid use to treat Duchenne in early 2025.

Learn more about the vamorolone programme here.